LJI Wealth Management LLC acquired a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 185,000 shares of the company's stock, valued at approximately $934,000. LJI Wealth Management LLC owned 0.15% of Humacyte at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in the company. State Street Corp increased its holdings in Humacyte by 66.1% during the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company's stock worth $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Humacyte during the third quarter valued at about $596,000. Thrivent Financial for Lutherans purchased a new position in Humacyte during the third quarter worth about $712,000. Barclays PLC grew its position in Humacyte by 177.6% in the 3rd quarter. Barclays PLC now owns 236,742 shares of the company's stock worth $1,288,000 after purchasing an additional 151,458 shares in the last quarter. Finally, Brookstone Capital Management purchased a new stake in Humacyte in the 4th quarter valued at about $56,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms have recently issued reports on HUMA. BTIG Research reaffirmed a "buy" rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. Piper Sandler set a $6.00 price target on Humacyte and gave the company a "neutral" rating in a research report on Friday, October 18th. Benchmark lifted their price objective on Humacyte from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, December 23rd. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Tuesday, January 21st. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $13.71.
Check Out Our Latest Stock Analysis on Humacyte
Insider Activity
In other news, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the firm's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. This represents a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 in the last three months. Corporate insiders own 11.20% of the company's stock.
Humacyte Stock Down 1.2 %
NASDAQ:HUMA traded down $0.05 during mid-day trading on Wednesday, hitting $3.96. 1,980,890 shares of the stock traded hands, compared to its average volume of 2,282,117. The business's 50-day moving average price is $4.51 and its 200 day moving average price is $5.33. The company has a market cap of $498.41 million, a PE ratio of -2.96 and a beta of 1.30. Humacyte, Inc. has a 12-month low of $2.81 and a 12-month high of $9.97.
About Humacyte
(
Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Read More
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
